-
Product Insights
New![]()
Net Present Value Model: Scholar Rock Holding Corp’s SRK-181
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SRK-181 in Ovarian Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SRK-181 in Ovarian Cancer Drug Details: SRK-181 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SRK-181 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SRK-181 in Solid Tumor Drug Details: SRK-181 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SRK-181 in Oropharyngeal Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SRK-181 in Oropharyngeal Cancer Drug Details: SRK-181 is under development for the treatment...
-
Product Insights
Vito-Poshtova SRK – 96b-Zvenyhorodska Street Preschool – Kyiv City
Equip yourself with the essential tools needed to make informed and profitable decisions with our Vito-Poshtova SRK - 96b-Zvenyhorodska Street Preschool - Kyiv City report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
New![]()
Net Present Value Model: Scholar Rock Holding Corp’s Apitegromab
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Scholar Rock Holding Corp's Apitegromab Drug Details: Apitegromab (SRK-015) is under development for the treatment of type 2 and type 3 spinal muscular...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Apitegromab in Spinal Muscular Atrophy (SMA)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDataÂ’s proprietary machine learning algorithms developed using over 10 years of historical data. Apitegromab in Spinal Muscular Atrophy (SMA) Drug Details: Apitegromab (SRK-015) is under development for...
-
Sector Analysis
South Africa Construction Market Size, Trend Analysis by Sector, Competitive Landscape and Forecast to 2027
South Africa Construction Market Report Overview The South Africa construction market size was valued at $25.5 billion in 2022 and is expected to achieve an AAGR of more than 3% from 2024 to 2027. The South African construction industry has been declining since 2016, but it will start to show some improvement in 2024, supported by investments in transport, renewable energy, and water infrastructure projects. Forecast-period growth in the industry will also be supported by investments as part of the...
-
Product Insights
![]()
Net Present Value Model: SRK-181
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model SRK-181 Drug Details SRK-181 is under...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – SRK-001
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry SRK-001 Drug Details SRK-001 is under development for the treatment of systemic lupus erythematosus...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – SRK-181
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry SRK-181 Drug Details SRK-181 is under development for the treatment of solid tumors including...
-
Report Bundle
53% offFuture of Construction in the Middle East and Africa – Report Bundle (7 Reports)
Future of Construction in MEA Bundle Overview The construction industry plays a significant role in the development of a country. Governments across many countries are making investments to revive this sector after the COVID-19 pandemic’s impact, as it will generate employment. In the long run, this will help in the overall growth of the economy. Each report within the bundle allows you to access in-depth analysis of the construction industry of the respective countries. The reports provide – Historical (2018-2022)...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – apitegromab
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry apitegromab Drug Details Apitegromab (SRK-015) is under development for the treatment of type 2...
-
Product Insights
Spinal Muscular Atrophy (SMA) Disease – Global Clinical Trials Review, H1 2020
GlobalData's clinical trial report, “Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H1, 2020" provides an overview of Spinal Muscular Atrophy (SMA) Clinical trials scenario. This report provides top line data relating to the clinical trials on Spinal Muscular Atrophy (SMA). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “Spinal Muscular Atrophy (SMA) Global Clinical Trials Review, H2, 2018" provides an overview of Spinal Muscular Atrophy (SMA) clinical trials scenario. This report provides top line data relating to the clinical trials on Spinal Muscular Atrophy (SMA). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.